Group 1 - The company has decided to reappoint Beijing Dehao International Accounting Firm as the auditor for the fiscal year 2025, pending approval from the shareholders' meeting [2][12][13] - The audit fee for the current period is set at 1.2 million RMB, which includes 800,000 RMB for financial audit and 400,000 RMB for internal control audit, reflecting an increase of 200,000 RMB from the previous year [10][12] - The audit committee and board of directors have reviewed and approved the reappointment, citing the firm's diligence, independence, and professional competence [11][12][13] Group 2 - The company’s subsidiary, Yanji Pharmaceutical, has received a drug supplement application approval notice for Metronidazole and Fenbufen Capsules, allowing the transfer of the marketing authorization holder from Harbin Huari Biochemical Pharmaceutical Co., Ltd. to Yanji Pharmaceutical [38][39] - The drug is indicated for conditions such as gingivitis and periodontitis, which may enhance the company's product offerings and competitive edge in the market [41]

格隆汇8月29日丨吉林敖东(000623.SZ)公布，近日，吉林敖东药业集团股份有限公司控股子公司吉林敖 东药业集团延吉股份有限公司(简称「延吉药业」)收到国家药品监督管理局下发的「甲硝唑芬布芬胶 囊」的《药品补充申请批准通知书》。 获批准该品上市许可持有人由「哈尔滨华瑞生化药业有限责任公司(地址：哈尔滨利民经济技术开发区 上海大街7号)」变更为「吉林敖东药业集团延吉股份有限公司(地址：吉林省延吉市高新技术开发区长 白路389号)」，药品批准文号不变。转让药品的生产场地、处方、生产工艺、质量标准等与原药品一 致，不发生变更。 ...

格隆汇8月29日丨吉林敖东(000623.SZ)公布，近日，吉林敖东药业集团股份有限公司控股子公司吉林敖 东药业集团延吉股份有限公司(简称"延吉药业")收到国家药品监督管理局下发的"甲硝唑芬布芬胶囊"的 《药品补充申请批准通知书》。 获批准该品上市许可持有人由"哈尔滨华瑞生化药业有限责任公司(地址：哈尔滨利民经济技术开发区上 海大街7号)"变更为"吉林敖东药业集团延吉股份有限公司(地址：吉林省延吉市高新技术开发区长白路 389号)"，药品批准文号不变。转让药品的生产场地、处方、生产工艺、质量标准等与原药品一致，不 发生变更。 ...